Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 19 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016.
- 12 Aug 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
- 29 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.